breast cancer

Research in Review

Steep Increases in Genetic Test Cancellations Seen Following Mandated Genetic Counseling

12/13/2016

JCP Editors

Insurance-mandated genetic counseling prior to hereditary cancer genetic testing significantly increased test cancellation rates, particularly among minority patients, according to research published in Journal of...

...

12/13/2016

Journal of Clinical Pathways

Research in Review

Hormone Receptor-Negative Breast Cancers Gain Greatest Economic Benefit from Trastuzumab

12/13/2016

JCP Editors

The cost-effectiveness of adjuvant trastuzumab (Herceptin, Genentech) may vary based on patient age and disease subtype among women with HER2-positive breast cancer, according to study results published in PLoS...

The...

12/13/2016

Journal of Clinical Pathways

News

IBM‚Äôs Watson Agrees With Oncologist Treatment Decisions 90% of the Time

12/12/2016

JCP Editors

IBM’s Watson for Oncology, a computer that helps oncologists make treatment decisions for individual patients, made the same recommendations 90% of the time as a team of specialist oncologists, according to a new...

IBM’s...

12/12/2016

Journal of Clinical Pathways

Research in Review

Trastuzumab Biosimilar Approval Could Improve Access to Treatment For Breast Cancer

12/05/2016

JCP Editors

The potential FDA approval of a new biosimilar to trastuzumab may help increase access to the treatment, which is recommended as first-line therapy for patients with ERBB2 (HER2)-positive breast...

The...

12/05/2016

Journal of Clinical Pathways

Research in Review

11/30/2016

JCP Editors

Two kinds of heart medications, angiotensin-converting enzyme (ACE) inhibitors and beta blockers, can help to prevent a decline in heart function from breast cancer treatment, according to new research published in...

Two...

11/30/2016

Journal of Clinical Pathways

Research in Review

Review Examines Prognostic Value of Tumor-Infiltrating Lymphocytes in Early Breast Cancer

11/15/2016

JCP Editors

Tumor-infiltrating lymphocytes (TILs) have been described in various tumors, including breast cancer. In early breast cancer, the presence of TILs is associated with better outcomes and response to therapy. A review...

...

11/15/2016

Journal of Clinical Pathways

Research in Review

Study Examines Cost-Effectiveness of Treatment Sequencing for HER2-Positive Breast Cancer

11/15/2016

JCP Editors

Targeted therapies have been shown to significantly improve the survival of patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer. However, these therapies have also been associated...

...

11/15/2016

Journal of Clinical Pathways

Research in Review

NET Equally Effective, Safer Than Neoadjuvant Chemotherapy for ER+ Breast Cancer

11/11/2016

JCP Editors

Neoadjuvant endocrine therapy may be just as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast cancer with considerably fewer adverse events, according to a...

...

11/11/2016

Journal of Clinical Pathways

Research in Review

Tamoxifen May Reduce Contralateral Breast Cancer Risk

10/11/2016

JCP Editors

Adjuvant endocrine therapy with tamoxifen or aromatase inhibitors may reduce the risk for contralateral breast cancer (CBC) in women with invasive breast cancer according to results from a study published in JAMA...

...

10/11/2016

Journal of Clinical Pathways

Research in Review

Tumor Genetics Can Change During Treatment for ER+ Breast Cancer

08/12/2016

JCP Editors

Treating human estrogen-receptor (ER)-positive breast cancer tumors with estrogen-deprivation therapy can change the spectrum of mutations in the tumor population, affecting treatment response, according to research...

...

08/12/2016

Journal of Clinical Pathways